SCHEMBL2834586

SCHEMBL2834586

O=C(NS(=O)(=O)c1cccc([N+](=O)[O-])c1NCCn1ccnn1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1Oc1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830475 0.92 — —
SCHEMBL1954719 0.90 BCL2 (0.74) —
SCHEMBL2829630 0.90 — —
SCHEMBL2828999 0.88 BCL2 (0.63) —
SCHEMBL2830501 0.87 — —
SCHEMBL19424766 0.84 BCL2 (0.63) —
SCHEMBL18274762 0.84 BCL2 (0.66) —
SCHEMBL1957757 0.81 BCL2 (0.78) —
SCHEMBL1743602 0.80 — —
SCHEMBL1742960 0.79 BCL2 (0.72) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563735-B2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE INC. (US) 2013-10-22 — — US disclosed
US-20100152183-A1 BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-17 — — US disclosed
Send feedback